HIMS / Hims & Hers Health, Inc. - Depositi SEC, Relazione annuale, dichiarazione di delega

HIMS, INC., AS TENANT MENDEL NEW ALBANY PROPERTY OWNER LLC, AS LANDLORD 9885 INNOVATION CAMPUS WAY, NEW ALBANY, OHIO

LEASE BETWEEN HIMS, INC., AS TENANT AND MENDEL NEW ALBANY PROPERTY OWNER LLC, AS LANDLORD 9885 INNOVATION CAMPUS WAY, NEW ALBANY, OHIO The submission of an unsigned copy of this document to Tenant for Tenant’s consideration does not constitute an offer to lease the Premises or an option to or for the Premises. This document shall become effective and binding only upon the execution and delivery of

[Signature on Following Page]

GUARANTY This Guaranty is made as of September 1, 2025 by HIMS & HERS HEALTH, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2025 HIMS & HERS HEA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2025 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2025 HIMS & HERS HEALTH

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2025 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO S

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact name

Feeling good in your body & mind transforms how you show up in life. That’s why we’re on a mission to help the world feel great through the power of better health. 2 Hims & Hers Q2 2025 Key Financial Highlights Q2 2025 Q2 2024 Growth Revenue $545M $3

finalq22025shareholderle Feeling good in your body & mind transforms how you show up in life.

Amendment No. 1, dated as of June 25, 2025, by and among Hims & Hers Health, Inc. and JPMorgan Chase Bank, N.A., as administrative agent, to that certain Credit Agreement dated as of February 18, 2025.*

hims-20250630x10qxex103 Execution Version 1 AMENDMENT NO. 1 THIS AMENDMENT NO. 1 (this “Amendment”), dated as of June 25, 2025, by and among HIMS & HERS HEALTH, INC., a Delaware corporation (the “Borrower”), and JPMORGAN CHASE BANK, N.A. in its capacity as the Administrative Agent under the Existing Credit Agreement (as defined below), amends that certain Credit Agreement, dated as of February 18,

Hims & Hers Health, Inc. Reports Second Quarter 2025 Financial Results Revenue of $544.8 million, up 73% year-over-year in Q2 2025 Net income of $42.5 million; Adjusted EBITDA of $82.2 million in Q2 2025 Subscribers grew to over 2.4 million, up 31% y

Hims & Hers Health, Inc. Reports Second Quarter 2025 Financial Results Revenue of $544.8 million, up 73% year-over-year in Q2 2025 Net income of $42.5 million; Adjusted EBITDA of $82.2 million in Q2 2025 Subscribers grew to over 2.4 million, up 31% year-over-year in Q2 2025 Affirms full year 2025 revenue guidance of $2.3 billion to $2.4 billion and Adjusted EBITDA guidance of $295 million to $335

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 HIMS & HERS HEALTH,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission

Indenture, dated as of May 13, 2025, between Hims & Hers Health, Inc. and U.S. Bank Trust Company, National Association, as trustee.

Exhibit 4.1 EXECUTION VERSION HIMS & HERS HEALTH, INC. and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of May 13, 2025 0.00% Convertible Senior Notes due 2030 TABLE OF CONTENTS Page Article 1. Definitions; Rules of Construction 1    Section 1.01. Definitions 1 Section 1.02. Other Definitions 13 Section 1.03. Rules of Construction 14 Article 2. The Notes 15 Section 2

Form of Confirmation of Base Call Option Transaction.

Exhibit 10.1 [Dealer Name and Address] May [], 2025 To: Hims & Hers Health, Inc. 2269 Chestnut Street #523 San Francisco, CA 94123 Attention: Legal Department Re: Base Call Option Transaction The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between [Dealer Name] (“Dealer”) and Hims & Hers Health, Inc. (“Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 HIMS & HERS HEALTH,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission F

Form of Confirmation of Additional Call Option Transaction.

Exhibit 10.2 [Dealer Name and Address] May [ ], 2025       To: Hims & Hers Health, Inc. 2269 Chestnut Street #523 San Francisco, CA 94123 Attention: Legal Department Re: Additional Call Option Transaction The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between [Dealer Name] (“Dealer”) and Hims & Hers Heal

Hims & Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Accelerate Global Expansion and Utilization of AI in Healthcare

EX-99.1 Exhibit 99.1 Hims & Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Accelerate Global Expansion and Utilization of AI in Healthcare • Proceeds intended to support Hims & Hers’ global expansion through organic growth and strategic acquisitions, while also fueling deeper investment in AI, diagnostics, and personalized treatments to scale access and meet rising deman

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 HIMS & HERS HEALTH, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission Fi

Hims & Hers Health, Inc. Prices Upsized $870.0 Million Convertible Senior Notes Offering to Accelerate Global Expansion and Utilization of AI in Healthcare

Exhibit 99.2 Hims & Hers Health, Inc. Prices Upsized $870.0 Million Convertible Senior Notes Offering to Accelerate Global Expansion and Utilization of AI in Healthcare Proceeds intended to support Hims & Hers’ global expansion through organic growth and strategic acquisitions, while also fueling deeper investment in AI, diagnostics, and personalized treatments to scale access and meet rising dema

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 HIMS & HERS HEALTH, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission Fi

Warehouse Lease Agreement by and between COI New Albany Industrial 300, LLC, and Hims, Inc.

Andrew Dudum CEO

60orm iHSA100 milf595100 m Feeling good in your body & mind transforms how you show up in life. That’s why we’re on a mission to help the world feel great through the power of better health. 2 Hims & Hers Q1 2025 * This is a non-GAAP financial measur

60orm iHSA100 milf595100 m Feeling good in your body & mind transforms how you show up in life.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact name

Hims & Hers Health, Inc. Reports First Quarter 2025 Financial Results Revenue of $586.0 million, up 111% year-over-year in Q1 2025 Net income of $49.5 million; Adjusted EBITDA of $91.1 million in Q1 2025 Subscribers grew to 2.4 million, up 38% year-o

Hims & Hers Health, Inc. Reports First Quarter 2025 Financial Results Revenue of $586.0 million, up 111% year-over-year in Q1 2025 Net income of $49.5 million; Adjusted EBITDA of $91.1 million in Q1 2025 Subscribers grew to 2.4 million, up 38% year-over-year in Q1 2025 Affirms full year 2025 revenue guidance of $2.3 billion to $2.4 billion and raises Adjusted EBITDA guidance to a range of $295 mil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ De

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2025 HIMS & HERS HEALTH

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2025 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission

Hims & Hers Health, Inc. | 2269 Chestnut Street, #523 | San Francisco, CA 94123

VIA EDGAR April 14, 2025 Securities and Exchange Commission Division of Corporate Finance 100 F Street, NE Washington, D.

As filed with the Securities and Exchange Commission on February 24, 2025

As filed with the Securities and Exchange Commission on February 24, 2025 Registration No.

Industrial Building Lease Agreement by and between LPC Mesa Gateway, LP and Hims, Inc., dated January 17, 2025 (incorporated by reference to Exhibit 10.12 to the Registrant’s Form 10-K for the period ended December 31, 2024 filed with the SEC on February 24, 2025).

SINGLE-TENANT INDUSTRIAL BUILDING LEASE Between LPC MESA GATEWAY, LP Landlord, and HIMS, INC.

List of Subsidiaries

Exhibit 21 SUBSIDIARIES OF HIMS & HERS HEALTH, INC. DOMESTIC COMPANIES Name Jurisdiction of Incorporation Hims, Inc. Delaware H&H Healthcare Management, Inc. Delaware H&H Pharmacy Management, Inc. Delaware H&H Pharmacy Holdings, Inc. Delaware H&H Peptides, Inc. Delaware H&H Labs, LLC Delaware Seaview Enterprises LLC California FOREIGN COMPANIES Name Jurisdiction of Incorporation Hims & Hers UK Lim

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2025 HIMS & HERS HEA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2025 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commiss

Insider Trading Policy*

Hims & Hers Health, Inc. Insider Trading Policy Table of Contents Page Section I - Introduction 1 A. Legal Prohibitions on Insider Trading 1 B. Detection and Prosecution of Insider Trading 1 C. Penalties for Violation of Insider Trading Laws and This Policy 1 D. The Chief Legal Officer and the Chief Financial Officer Duties & Responsibilities 2 E. Reporting Violations 2 F. Personal Responsibility

Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results Revenue of $1.5 billion, up 69% year-over-year in 2024 Net income of $126 million; Adjusted EBITDA of $177 million in 2024 Subscribers grew to 2.2 million, up 45% ye

Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results Revenue of $1.5 billion, up 69% year-over-year in 2024 Net income of $126 million; Adjusted EBITDA of $177 million in 2024 Subscribers grew to 2.2 million, up 45% year-over-year in 2024 Provides Q1 and full year 2025 guidance, with full year 2025 revenue in the range of $2.3 billion to $2.4 billion and Adjusted EB

Filing Fee Table

Calculation of Filing Fee Tables S-8 Hims & Hers Health, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Class A common Stock, par value $0.0001 per share Other 11,041,860 $ 53.21 $ 587,537,370.60 0.0001531 $ 89,9

iHSA100 milf595100 m Feeling good in your body & mind transforms how you show up in life. That’s why we’re on a mission to help the world feel great through the power of better health. 2 Hims & Hers Q4 2024 * This is a non-GAAP financial measure. Ple

iHSA100 milf595100 m Feeling good in your body & mind transforms how you show up in life.

ent Contractor Advisor Agreement, dated November 15, 2024, by and between

INDEPENDENT CONTRACTOR ADVISOR AGREEMENT Effective as of the date the Board of Directors of Hims & Hers Health, Inc.

eement, dated as of February 18, 2025, among Hims & Hers Health,

REVOLVING CREDIT AND GUARANTY AGREEMENT dated as of February 18, 2025, among HIMS & HERS HEALTH, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact name of r

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2024 HIMS & HERS HEA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2024 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commiss

100 milf595100 m Feeling good in your body & mind transforms how you show up in life. That’s why we’re on a mission to help the world feel great through the power of better health. 2 Hims & Hers Q3 2024 Key Financial Highlights Q3 2024 Q3 2023 Growth

100 milf595100 m Feeling good in your body & mind transforms how you show up in life.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2024 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact

Hims & Hers Health, Inc. Reports Third Quarter 2024 Financial Results Revenue of $401.6 million, up 77% year-over-year in Q3 2024 Net income of $75.6 million; Adjusted EBITDA of $51.1 million in Q3 2024 Subscribers grew to 2.0 million, up 44% year-ov

Hims & Hers Health, Inc. Reports Third Quarter 2024 Financial Results Revenue of $401.6 million, up 77% year-over-year in Q3 2024 Net income of $75.6 million; Adjusted EBITDA of $51.1 million in Q3 2024 Subscribers grew to 2.0 million, up 44% year-over-year in Q3 2024 Raises full year 2024 revenue guidance to a range of $1.460 billion to $1.465 billion and Adjusted EBITDA guidance to a range of $1

LIMITED POWER OF ATTORNEY

EX-99.1 2 d898514dex991.htm EX-99.1 Exhibit 99.1 LIMITED POWER OF ATTORNEY Know all by these present, that I, Andrew Dudum, hereby make, constitute and appoint Soleil Boughton, Alexandra Cotter Wilkins and Kimberly Mather, acting individually, and with full power of substitution, as my true and lawful attorney-in-fact for the purpose of executing in my name, (a) in my personal capacity or (b) in m

HIMS / Hims & Hers Health, Inc. / Dudum Andrew - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Hims & Hers Health, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value (Title of Class of Securities) 433000 106 (CUSIP Number) Andrew Dudum 2269 Chestnut Street, #523 San Francisco, California 94123 (415) 851-0195 (Name, Address an

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2024 HIMS & HERS HEA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2024 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commiss

976,341 shares of Class A Common Stock Offered by the Selling Stockholder

TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(7)  Registration No. 333-282008 PROSPECTUS SUPPLEMENT (to Prospectus dated September 9, 2024) 976,341 shares of Class A Common Stock Offered by the Selling Stockholder This prospectus supplement relates to the potential offer and resale of up to 976,341 shares of Class A common stock (the “Resale Shares”) of Hims & Hers Health, Inc. (the “Company,”

Table 1: Newly Registered and Carry Forward Securities

Calculation of Filing Fee Tables S-3 Hims & Hers Health, Inc. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective

Form of Indenture with respect to Debt Securities.

Exhibit 4.3 HIMS & HERS HEALTH, INC. and [ ], as Trustee Indenture Dated as of [ ] Debt Securities CROSS REFERENCE SHEET* Between Provisions of Trust Indenture Act (as defined herein) and Indenture, dated as of [], between HIMS & HERS HEALTH, INC. and [], as Trustee: SECTION OF THE ACT SECTION OF INDENTURE 310(a)(1) and (2) 6.9 310(a)(3) and (4) Inapplicable 310(b) 6.8 and 6.10(a), (b) and (d) 310

As filed with the Securities and Exchange Commission on September 9, 2024

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on September 9, 2024 Registration No.

Filing Fee Table.

Calculation of Filing Fee Tables S-3 Hims & Hers Health, Inc. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective

Hims & Hers Health, Inc. Reports Second Quarter 2024 Financial Results Revenue of $315.6 million, up 52% year-over-year in Q2 2024 Net income of $13.3 million; Adjusted EBITDA of $39.3 million in Q2 2024 Subscribers grew to 1.9 million, up 43% year-o

Hims & Hers Health, Inc. Reports Second Quarter 2024 Financial Results Revenue of $315.6 million, up 52% year-over-year in Q2 2024 Net income of $13.3 million; Adjusted EBITDA of $39.3 million in Q2 2024 Subscribers grew to 1.9 million, up 43% year-over-year in Q2 2024 Raises full year 2024 revenue guidance to a range of $1.37 billion to $1.40 billion and Adjusted EBITDA guidance to a range of $14

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 HIMS & HERS HEALTH

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission

Feeling good in your body & mind transforms how you show up in life. That’s why we’re on a mission to help the world feel great through the power of better health. 2 Hims & Hers Q2 2024 Key Financial Highlights Q2 2024 Q2 2023 Growth Revenue $315.6M

finalq22024shareholderle Feeling good in your body & mind transforms how you show up in life.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2024 HIMS & HERS HEALTH,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2024 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2024 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission F

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2024 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commissi

HIMS / Hims & Hers Health, Inc. / Institutional Venture Management XVI, LLC - SC 13D/A Activist Investment

SC 13D/A 1 tm2415368d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Hims & Hers Health, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 433000 106 (CUSIP Number) Tracy Hogan Institutional Venture Partners 3000 Sand Hill Road Bu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact name

Hims & Hers Health, Inc. Reports First Quarter 2024 Financial Results Revenue of $278.2 million, up 46% year-over-year in 2024 Net income of $11.1 million; Adjusted EBITDA of $32.3 million in Q1 2024 Subscribers grew to 1.7 million, up 41% year-over-

Hims & Hers Health, Inc. Reports First Quarter 2024 Financial Results Revenue of $278.2 million, up 46% year-over-year in 2024 Net income of $11.1 million; Adjusted EBITDA of $32.3 million in Q1 2024 Subscribers grew to 1.7 million, up 41% year-over-year in Q1 2024 Raises full year 2024 guidance to a range of $1.20 billion to $1.23 billion and Adjusted EBITDA to a range of $120 million to $135 mil

Feeling good in your body & mind transforms how you show up in life. That’s why we’re on a mission to help the world feel great through the power of better health. 2 Hims & Hers Q1 2024 Key Financial Highlights Q1 2024 Q1 2023 Growth Revenue $278.2M

finalflatq12024sharehold Feeling good in your body & mind transforms how you show up in life.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 HIMS & HERS HEALTH, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2024 HIMS & HERS HEALTH

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2024 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2024 HIMS & HERS HEAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2024 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ De

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2024 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission

HIMS / Hims & Hers Health, Inc. / Institutional Venture Management XVI, LLC - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.

Policy Relating to Recovery of Erroneously Awarded Compensation

Recovery of Erroneously Awarded Compensation Policy 1.Purpose. The purpose of this Policy is to describe the circumstances in which Executive Officers will be required to repay or return Erroneously Awarded Compensation to members of the Company Group. This Policy is designed to comply with, and shall be interpreted to be consistent with, Section 10D of the Securities Exchange Act of 1934, as amen

Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results Revenue of $872.0 million, up 65% year-over-year in 2023 Net income of $1.2 million; Adjusted EBITDA profitability of $20.6 million in Q4 2023 Subscribers grew to 1.

Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results Revenue of $872.0 million, up 65% year-over-year in 2023 Net income of $1.2 million; Adjusted EBITDA profitability of $20.6 million in Q4 2023 Subscribers grew to 1.5 million, up 48% year-over-year in Q4 2023 Provides Q1 and full year 2024 guidance, with full year 2024 revenue in the range of $1.17 billion to $1.2

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Hims & Hers Health, Inc.

Shareholder Letter dated February 26, 2024

As filed with the Securities and Exchange Commission on February 26, 2024

As filed with the Securities and Exchange Commission on February 26, 2024 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact name of r

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2024 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commiss

HIMS / Hims & Hers Health, Inc. / Abraham Jack Passive Investment

SC 13G/A 1 hims13ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 3)* Hims & Hers Health, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value per share (Title of Class of Securities) 433000

HIMS / Hims & Hers Health, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01124-himshershealthinccla.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Hims & Hers Health, Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 433000106 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropria

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 HIMS & HERS HEAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact

Hims & Hers Health, Inc. Reports Third Quarter 2023 Financial Results and Raises Full Year 2023 Outlook Revenue of $226.7 million, up 57% year-over-year in Q3 2023 Net loss of $7.6 million; Adjusted EBITDA profitability of $12.3 million in Q3 2023 Su

Hims & Hers Health, Inc. Reports Third Quarter 2023 Financial Results and Raises Full Year 2023 Outlook Revenue of $226.7 million, up 57% year-over-year in Q3 2023 Net loss of $7.6 million; Adjusted EBITDA profitability of $12.3 million in Q3 2023 Subscribers grew to 1.4 million, up 56% year-over-year in Q3 2023 Exited Q3 2023 with over 80% of orders fulfilled via affiliated facilities Raises full

Hims & Hers Health, Inc. Reports Second Quarter 2023 Financial Results and Raises Full Year 2023 Outlook Revenue of $207.9 million, up 83% year-over-year in Q2 2023 Net loss of $7.2 million; Adjusted EBITDA profitability of $10.6 million in Q2 2023 S

Hims & Hers Health, Inc. Reports Second Quarter 2023 Financial Results and Raises Full Year 2023 Outlook Revenue of $207.9 million, up 83% year-over-year in Q2 2023 Net loss of $7.2 million; Adjusted EBITDA profitability of $10.6 million in Q2 2023 Subscribers grew to 1.3 million, up 74% year-over-year in Q2 2023 Raises full year 2023 revenue guidance to a range of $830 million to $850 million and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 HIMS & HERS HEALTH

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 HIMS & HERS HEALTH,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission F

HIMS / Hims & Hers Health Inc - Class A / NewView Capital Fund I, L.P. - SC 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 1)* Hims & Hers Health, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 (Title of Class of Securities) 433000106 (CUSIP Number) December 31, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 HIMS & HERS HEALTH, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission Fi

Hims & Hers Health, Inc. Reports First Quarter 2023 Financial Results and Raises Full Year 2023 Outlook Revenue of $190.8 million, up 88% year-over-year in Q1 2023 Net loss of $10.1 million; Adjusted EBITDA profitability of $6.1 million in Q1 2023 Su

Hims & Hers Health, Inc. Reports First Quarter 2023 Financial Results and Raises Full Year 2023 Outlook Revenue of $190.8 million, up 88% year-over-year in Q1 2023 Net loss of $10.1 million; Adjusted EBITDA profitability of $6.1 million in Q1 2023 Subscribers grew to over 1.2 million, up 87% year-over-year in Q1 2023 Raises full year 2023 revenue guidance to a range of $810 million to $830 million

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rul

HIMS / Hims & Hers Health Inc - Class A / Institutional Venture Management XVI, LLC - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.

HIMS / Hims & Hers Health Inc - Class A / Redpoint Ventures VI, L.P. - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.

HIMS / Hims & Hers Health Inc - Class A / Forerunner Partners III, L.P. - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.

As filed with the Securities and Exchange Commission on February 28, 2023

As filed with the Securities and Exchange Commission on February 28, 2023 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Hims & Hers Health, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2023 HIMS & HERS HEA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2023 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commiss

Hims & Hers Health, Inc. 2020 Equity Incentive Plan and forms of agreement thereunder (incorporated by reference to Exhibit 10.

Hims & Hers Health, Inc. 2020 Equity Incentive Plan (As Adopted and approved by the Stockholders) Hims & Hers Health, Inc. 2020 Equity Incentive Plan ARTICLE 1. INTRODUCTION. The Board adopted the Plan to become effective immediately prior to the Closing (as defined in the Merger Agreement). The purpose of the Plan is to promote the long-term success of the Company and the creation of stockholder

Exhibit 4.2

Exhibit 4.2 DESCRIPTION OF THE COMPANY’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED Authorized Capitalization The total amount of our authorized capital stock consists of 2,750,000,000 shares of Class A common stock, par value $0.0001 per share, 10,000,000 shares of Class V common stock, par value $0.0001 per share, and 275,000,000 shares of pre

Hims & Hers Health, Inc. Reports Record Fourth Quarter and Full Year 2022 Financial Results Full year 2022 revenue of $526.9 million, up 94% year-over-year Q4 2022 record revenue of $167.2 million, up 97% year-over-year Q4 2022 net loss of $10.9 mill

Hims & Hers Health, Inc. Reports Record Fourth Quarter and Full Year 2022 Financial Results Full year 2022 revenue of $526.9 million, up 94% year-over-year Q4 2022 record revenue of $167.2 million, up 97% year-over-year Q4 2022 net loss of $10.9 million and achieves Adjusted EBITDA profitability of $3.9 million Eclipses one million subscribers at year end, up 88% year-over-year Provides Q1 and ful

Form of Change in Control and Severance Agreement

HIMS, INC. FORM OF CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control Severance Agreement (the “Agreement”) is made and entered into by and between [NAME OF EMPLOYEE OR DIRECTOR] (the “Executive”) and Hims, Inc., a Delaware corporation (the “Company”), effective as of the date specified in Section 1 below. This Agreement provides severance and acceleration benefits in connection with

List of Subsidiaries*

Exhibit 21 SUBSIDIARIES OF HIMS & HERS HEALTH, INC. DOMESTIC COMPANIES Name Jurisdiction of Incorporation Hims, Inc. Delaware H&H Derm, LLC Delaware H&H Healthcare Management, Inc. Delaware H&H Pharmacy Management, Inc. Delaware FOREIGN COMPANIES Name Jurisdiction of Incorporation Hims & Hers UK Limited United Kingdom

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTI

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact name of r

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2023 HIMS & HERS HEA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2023 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commiss

HIMS / Hims & Hers Health, Inc. / NewView Capital Fund I, L.P. - SC 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. )* Hims & Hers Health, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 (Title of Class of Securities) 433000106 (CUSIP Number) December 31, 2022 (

HIMS / Hims & Hers Health, Inc. / Abraham Jack Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 2)* Hims & Hers Health, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value per share (Title of Class of Securities) 433000 106 (CUSIP Number) Decem

HIMS / Hims & Hers Health, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Hims & Hers Health Inc. Title of Class of Securities: Common Stock CUSIP Number: 433000106 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is file

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 HIMS & HERS HEAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commissi

Hims & Hers Health, Inc. Reports Third Quarter 2022 Financial Results and Raises Full Year 2022 Outlook; Platform Demand and Financial Outperformance Driving Expected Adjusted EBITDA Profitability Beginning in Q4 2022 Quarterly revenue of $144.8 mill

Hims & Hers Health, Inc. Reports Third Quarter 2022 Financial Results and Raises Full Year 2022 Outlook; Platform Demand and Financial Outperformance Driving Expected Adjusted EBITDA Profitability Beginning in Q4 2022 Quarterly revenue of $144.8 million in Q3 2022, up 95% year-over-year Consumer-centric strategy driving third straight quarterly gain of >100k net new subscriptions, ending Q3 2022 w

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact

Hims & Hers Health, Inc | 2269 Chestnut Street, #523 | San Francisco, CA 94123

VIA EDGAR October 11, 2022 Securities and Exchange Commission Division of Corporate Finance 100 F Street, NE Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO S

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact name

Hims & Hers Health, Inc. Reports Second Quarter 2022 Financial Results and Raises Full Year 2022 Outlook Quarterly revenue of $113.6 million in Q2 2022, up 87% year-over-year Consumer-centric strategy driving second straight quarterly gain of >100k n

Hims & Hers Health, Inc. Reports Second Quarter 2022 Financial Results and Raises Full Year 2022 Outlook Quarterly revenue of $113.6 million in Q2 2022, up 87% year-over-year Consumer-centric strategy driving second straight quarterly gain of >100k net new subscriptions, ending Q2 2022 with 817,000 subscriptions, up 80% year-over-year Raises full year 2022 revenue guidance to the range of $470 mil

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2022 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission F

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission Fi

Hims & Hers Health, Inc. Reports First Quarter 2022 Financial Results and Raises Full Year 2022 Revenue Outlook Quarterly revenue surpassed the $100 million mark to $101.3 million in Q1 2022, up 94% year-over-year Largest-ever quarterly gain in membe

Hims & Hers Health, Inc. Reports First Quarter 2022 Financial Results and Raises Full Year 2022 Revenue Outlook Quarterly revenue surpassed the $100 million mark to $101.3 million in Q1 2022, up 94% year-over-year Largest-ever quarterly gain in member subscriptions, increasing 101,000 in the quarter, ending Q1 2022 with 710,000 subscriptions, up 82% year-over-year Raises full year 2022 revenue gui

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.??) Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission Only (as permitte

Investor P

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2022 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission

As filed with the Securities and Exchange Commission on March 9, 2022

As filed with the Securities and Exchange Commission on March 9, 2022 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Hims & Hers Health, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTI

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact name of r

Change in Control and Severance Agreement, dated as of January 24, 2022, by and between Hims, Inc. and Oluyemi Okupe.*

HIMS, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control Severance Agreement (the ?Agreement?) is made and entered into by and between Oluyemi Okupe (the ?Executive?) and Hims, Inc., a Delaware corporation (the ?Company?), effective as of the date specified in Section 1 below. This Agreement provides severance and acceleration benefits in connection with certain qualifying termi

Employment Agreement, dated as of December 21, 2021, by and between Hims, Inc. and Oluyemi Okupe (incorporated by reference to Exhibit 10.12 to the Registrant’s Form 10-K filed with the SEC on February 24, 2022).

Hims, Inc. 2269 Chestnut #523 San Francisco, CA 94123 December 20, 2021 Oluyemi Okupe Re: Offer Letter and Employment Terms Dear Yemi, 1.Position. HIMS INC. and/or any of its past, present, and future parent companies, subsidiaries, predecessors, successors, affiliates, and acquisitions (the ?Company?) is pleased to offer you the position of Chief Financial Officer, on the following terms. Per the

Description of registered securities*

Exhibit 4.2 DESCRIPTION OF THE COMPANY?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED Authorized Capitalization The total amount of our authorized capital stock consists of 2,750,000,000 shares of Class A common stock, par value $0.0001 per share, 10,000,000 shares of Class V common stock, par value $0.0001 per share, and 275,000,000 shares of pre

List of Subsidiaries*

Exhibit 21 SUBSIDIARIES OF HIMS & HERS HEALTH, INC. DOMESTIC COMPANIES Name Jurisdiction of Incorporation Hims, Inc. Delaware H&H Derm, LLC Delaware H&H Healthcare Management, Inc. Delaware H&H Pharmacy Management, Inc. Delaware FOREIGN COMPANIES Name Jurisdiction of Incorporation Hims UK Limited United Kingdom Honest Health Linited United Kingdom

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2022 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commiss

Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides First Quarter and Full Year 2022 Outlook Exceeded Q4 2021 and full year 2021 revenue and Adjusted EBITDA guidance Full year revenue grew 83% year-over-y

Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides First Quarter and Full Year 2022 Outlook Exceeded Q4 2021 and full year 2021 revenue and Adjusted EBITDA guidance Full year revenue grew 83% year-over-year to $271.9 million. Q4 2021 revenue increased from Q3 2021 and grew 104% year-over-year to $84.7 million Q4 2021 ending member subscriptions grew 9

HIMS / Hims & Hers Health, Inc. / AMERIPRISE FINANCIAL INC - SC 13G/A Passive Investment

SC 13G/A 1 d315862dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment #1 Under the Securities and Exchange Act of 1934 Hims & Hers Health, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 433000106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate

to Schedule 13G Joint Filing Agreement

Exhibit II to Schedule 13G Joint Filing Agreement The undersigned persons agree and consent to the joint filing on their behalf of this Schedule 13G dated February 14, 2022 in connection with their beneficial ownership of Hims & Hers Health, Inc.

to Schedule 13G

Exhibit I to Schedule 13G Ameriprise Financial, Inc., a Delaware Corporation, is a parent holding company. The classification and identity of the relevant subsidiaries is as follows: Investment Adviser ? Columbia Management Investment Advisers, LLC is an investment adviser registered under section 203 of the Investment Advisers Act of 1940.

HIMS / Hims & Hers Health, Inc. / Abraham Jack Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2. (Amendment No. 1)* Hims & Hers Health, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value per share (Title of Class of Securities) 433000 106 (CUSIP Number) Decem

HIMS / Hims & Hers Health, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Hims & Hers Health Inc. Title of Class of Securities: Common Stock CUSIP Number: 433000106 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐

HIMS & HERS HEALTH, INC. 120,438,519 Shares of Class A Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-252814 PROSPECTUS HIMS & HERS HEALTH, INC. 120,438,519 Shares of Class A Common Stock This prospectus relates to the offer and sale from time to time by the selling securityholders named in this prospectus (the ?Selling Securityholders?) of up to 120,438,519 shares of our Class A common stock, par value $0.0001 per share (?Cla

HIMS / Hims & Hers Health, Inc. / Thrive Capital Partners V, L.P. - THRIVE CAPITAL PARTNERS V, L.P. / HIMS & HERS HEALTH -- SCHEDULE 13G/A(#1) Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1) * Hims & Hers Health, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value per share (Title of Class of Securities) 433000 106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to

As filed with the Securities and Exchange Commission on February 4, 2022.

Table of Contents As filed with the Securities and Exchange Commission on February 4, 2022.

Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2022 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 005-91087 98-1482650 (State or other jurisdiction of incorporation) (Commissi

Hims, Inc. and Subsidiaries Consolidated Financial Statements Years Ended December 31, 2020 and 2019 Contents Report of Independent Registered Public Accounting Firm 1 Consolidated Financial Statements Consolidated Balance Sheets as of December 31, 2

Exhibit 99.1 C ONSOLIDATED F INANCIAL S TATEMENTS Hims, Inc. and Subsidiaries Years Ended December 31, 2020 and 2019 With Report of Independent Registered Public Accounting Firm Hims, Inc. and Subsidiaries Consolidated Financial Statements Years Ended December 31, 2020 and 2019 Contents Report of Independent Registered Public Accounting Firm 1 Consolidated Financial Statements Consolidated Balance

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2022 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commissi

HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants

Filed Pursuant to Rule 424(b)(3) Registration No. 333-252814 PROSPECTUS SUPPLEMENT NO. 8 (to Prospectus dated June 3, 2021) HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants This prospectus supplement supplements the prospectus dated June 3, 2021 (the ?Prosp

HIMS / Hims & Hers Health, Inc. / Dudum Andrew - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Hims & Hers Health, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value (Title of Class of Securities) 433000 106 (CUSIP Number) Andrew Dudum 2269 Chestnut Street, #523 San Francisco, California 94123 (415) 851-0195 (Name, Address an

HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants

Filed Pursuant to Rule 424(b)(3) Registration No. 333-252814 PROSPECTUS SUPPLEMENT NO. 7 (to Prospectus dated June 3, 2021) HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants This prospectus supplement supplements the prospectus dated June 3, 2021 (the ?Prosp

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commiss

HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants

Filed Pursuant to Rule 424(b)(3) Registration No. 333-252814 PROSPECTUS SUPPLEMENT NO. 6 (to Prospectus dated June 3, 2021) HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants This prospectus supplement supplements the prospectus dated June 3, 2021 (the "Prosp

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commiss

Hims & Hers Health, Inc. Reports Third Quarter 2021 Financial Results Q3 2021 revenue grows 79% year-over-year to $74.2 million Q3 2021 ending member subscriptions grow 95% year-over-year to 551,000 Exceeds Q3 2021 revenue guidance, raises full year

Hims & Hers Health, Inc. Reports Third Quarter 2021 Financial Results Q3 2021 revenue grows 79% year-over-year to $74.2 million Q3 2021 ending member subscriptions grow 95% year-over-year to 551,000 Exceeds Q3 2021 revenue guidance, raises full year 2021 guidance SAN FRANCISCO, November 10, 2021 ? Hims & Hers Health, Inc. (?Hims & Hers?, NYSE: HIMS), a multi-specialty telehealth platform that conn

, 2021 announcing results for the quarter ended

Hims & Hers Health, Inc. Reports Third Quarter 2021 Financial Results Q3 2021 revenue grows 79% year-over-year to $74.2 million Q3 2021 ending member subscriptions grow 95% year-over-year to 551,000 Exceeds Q3 2021 revenue guidance, raises full year 2021 guidance SAN FRANCISCO, November 10, 2021 ? Hims & Hers Health, Inc. (?Hims & Hers?, NYSE: HIMS), a multi-specialty telehealth platform that conn

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact

HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants

Filed Pursuant to Rule 424(b)(3) Registration No. 333-252814 PROSPECTUS SUPPLEMENT NO. 5 (to Prospectus dated June 3, 2021) HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants This prospectus supplement supplements the prospectus dated June 3, 2021 (the "Prosp

SPENCER LEE TO STEP DOWN AS HIMS & HERS HEALTH CHIEF FINANCIAL OFFICER Smooth six month transition plan in place; The search for Company’s next CFO has begun; Company reaffirms Q3 and FY 2021 guidance

Exhibit 99.1 SPENCER LEE TO STEP DOWN AS HIMS & HERS HEALTH CHIEF FINANCIAL OFFICER Smooth six month transition plan in place; The search for Company?s next CFO has begun; Company reaffirms Q3 and FY 2021 guidance SAN FRANCISCO (September 7, 2021) - Hims & Hers Health, Inc. (?Hims & Hers?, NYSE: HIMS), the multi-specialty telehealth platform that provides modern personalized health and wellness ex

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2021 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commissio

HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants

Filed Pursuant to Rule 424(b)(3) Registration No. 333-252814 PROSPECTUS SUPPLEMENT NO. 4 (to Prospectus dated June 3, 2021) HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants This prospectus supplement supplements the prospectus dated June 3, 2021 (the ?Prosp

Warehouse Lease Agreement by and between COI New Albany Industrial 300, LLC, and Hims, Inc., dated January 27, 2020*†

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2021 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commissio

HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants

Filed Pursuant to Rule 424(b)(3) Registration No. 333-252814 PROSPECTUS SUPPLEMENT NO. 3 (to Prospectus dated June 3, 2021) HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants This prospectus supplement supplements the prospectus dated June 3, 2021 (the "Prosp

Hims & Hers Health, Inc. Reports Second Quarter 2021 Financial Results Q2 2021 revenue grows 69% year-over-year to $60.7 million Q2 2021 online revenue grows 75% year-over-year to $58.1 million Exceeds Q2 2021 guidance, raises full year 2021 expectat

Hims & Hers Health, Inc. Reports Second Quarter 2021 Financial Results Q2 2021 revenue grows 69% year-over-year to $60.7 million Q2 2021 online revenue grows 75% year-over-year to $58.1 million Exceeds Q2 2021 guidance, raises full year 2021 expectations SAN FRANCISCO, August 11, 2021 ? Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), a multi-specialty telehealth platform that connects consum

, 2021 announcing results for the quarter ended

Hims & Hers Health, Inc. Reports Second Quarter 2021 Financial Results Q2 2021 revenue grows 69% year-over-year to $60.7 million Q2 2021 online revenue grows 75% year-over-year to $58.1 million Exceeds Q2 2021 guidance, raises full year 2021 expectations SAN FRANCISCO, August 11, 2021 ? Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), a multi-specialty telehealth platform that connects consum

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO S

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact name

Hims & Hers Health, Inc. Incentive Bonus Plan*+

Hims & Hers Health, Inc. Incentive Bonus Plan ARTICLE 1.BACKGROUND AND PURPOSE 1.1Effective Date. This Plan became effective upon its adoption by the Committee and is not subject to approval by the Company?s stockholders. 1.2Purpose of the Plan. The Plan is intended to provide Participants with the possibility of earning incentive bonuses. ARTICLE 2.DEFINITIONS The following words and phrases shal

Warehouse Lease Agreement by and between COI New Albany Industrial 300, LLC, and Hims, Inc., dated January 27, 2020*†

Hims & Hers Health, Inc. Incentive Bonus Plan*+

Hims & Hers Health, Inc. Incentive Bonus Plan ARTICLE 1.BACKGROUND AND PURPOSE 1.1Effective Date. This Plan became effective upon its adoption by the Committee and is not subject to approval by the Company?s stockholders. 1.2Purpose of the Plan. The Plan is intended to provide Participants with the possibility of earning incentive bonuses. ARTICLE 2.DEFINITIONS The following words and phrases shal

HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants

Filed Pursuant to Rule 424(b)(3) Registration No. 333-252814 PROSPECTUS SUPPLEMENT NO. 2 (to Prospectus dated June 3, 2021) HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants This prospectus supplement supplements the prospectus dated June 3, 2021 (the "Prosp

EX-99.25

NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on August 20, 2021, pursuant to the provisions of Rule 12d2-2 (a).

HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants

Filed Pursuant to Rule 424(b)(3) Registration No. 333-252814 PROSPECTUS SUPPLEMENT NO. 1 (to Prospectus dated June 3, 2021) HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants This prospectus supplement supplements the prospectus dated June 3, 2021 (the ?Prosp

NOTICE OF REDEMPTION OF ALL OUTSTANDING WARRANTS (CUSIP 433000114)

Exhibit 99.2 July 9, 2021 NOTICE OF REDEMPTION OF ALL OUTSTANDING WARRANTS (CUSIP 433000114) Dear Warrant Holder, Hims & Hers Health, Inc. (the ?Company?) hereby gives notice that it is redeeming, at 5:00 p.m. New York City time on August 9, 2021 (the ?Redemption Date?), all of the Company?s outstanding warrants (the ?Warrants?) to purchase shares of the Company?s Class A common stock, par value $

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2021 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission F

Hims & Hers Announces Redemption of All Outstanding Warrants

Exhibit 99.1 Hims & Hers Announces Redemption of All Outstanding Warrants SAN FRANCISCO?(BUSINESS WIRE)? Hims & Hers Health, Inc. (?Hims & Hers? or the ?Company,? NYSE: HIMS), the multi-specialty telehealth platform focused on providing modern personalized health and wellness experiences to consumers, today announced that it will redeem all of its outstanding warrants (the ?Warrants?) to purchase

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2021 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2021 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission

HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants

Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-252814 PROSPECTUS HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants This prospectus relates to the offer and sale from time to time by the selling securityholders named in this prospectu

As filed with the Securities and Exchange Commission on June 2, 2021.

Table of Contents As filed with the Securities and Exchange Commission on June 2, 2021.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2021 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 ☐ TRANSITION REPORT PURSUANT TO

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact name

Hims & Hers Health, Inc. Reports First Quarter 2021 Financial Results Q1 2021 revenue grows 74% year-over-year to $52.3 million Q1 2021 gross margin of 77% compared to 69% in Q1 2020 Exceeds Q1 2021 guidance, raises full year 2021 revenue expectation

Hims & Hers Health, Inc. Reports First Quarter 2021 Financial Results Q1 2021 revenue grows 74% year-over-year to $52.3 million Q1 2021 gross margin of 77% compared to 69% in Q1 2020 Exceeds Q1 2021 guidance, raises full year 2021 revenue expectations SAN FRANCISCO, May 17, 2021 ? Hims & Hers Health, Inc. (?Hims & Hers?, NYSE: HIMS), a multi-specialty telehealth platform that connects consumers to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.?? ) Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission Only (as permitt

HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants

Filed Pursuant to Rule 424(b)(3) Registration No. 333-252814 PROSPECTUS SUPPLEMENT NO. 1 (to Prospectus dated March 23, 2021) HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants This prospectus supplement supplements the prospectus dated March 23, 2021 (the ?P

HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants

Filed Pursuant to Rule 424(b)(3) Registration No. 333-252814 PROSPECTUS SUPPLEMENT NO. 2 (to Prospectus dated March 23, 2021) HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants This prospectus supplement supplements the prospectus dated March 23, 2021 (the ?P

Regulation FD Disclosure, Financial Statements and Exhibits, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2021 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission Fi

Hims & Hers Health, Inc. Announces Response to Recent SEC Guidance Applicable to Warrants Issued by Special Purpose Acquisition Companies (“SPACs”)

Exhibit 99.1 Hims & Hers Health, Inc. Announces Response to Recent SEC Guidance Applicable to Warrants Issued by Special Purpose Acquisition Companies (?SPACs?) SAN FRANCISCO - (BUSINESS WIRE) - Hims & Hers Health, Inc. (?Hims & Hers?, NYSE: HIMS), a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, today announced that, as a result of guidance provi

Annual Report - 10-K/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact name of regi

- S-8

Table of Contents As filed with the Securities and Exchange Commission on March 29, 2021 Registration No.

HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants

Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-252814 PROSPECTUS HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants This prospectus relates to the offer and sale from time to time by the selling securityholders named in this prospectu

2

EX-99.2 Exhibit 99.2 HIMS’ MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis provides information that management believes is relevant to an assessment and understanding of Hims’ consolidated results of operations and financial condition. You should read the following discussion and analysis of Hims’ financial condition and

Description of registered securities (incorporated by reference to Exhibit 4.4 to the Original Filing).

Exhibit 4.4 DESCRIPTION OF THE COMPANY?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED Authorized Capitalization The total amount of our authorized capital stock consists of 2,750,000,000 shares of Class A common stock, par value $0.0001 per share, 10,000,000 shares of Class V common stock, par value $0.0001 per share, and 275,000,000 shares of pre

Hims, Inc. and Subsidiaries Consolidated Financial Statements Years Ended December 31, 2020 and 2019 Report of Independent Registered Public Accounting Firm 1 Consolidated Financial Statements Consolidated Balance Sheets as of December 31, 2020 and 2

EX-99.1 Exhibit 99.1 CONSOLIDATED FINANCIAL STATEMENTS Hims, Inc. and Subsidiaries Years Ended December 31, 2020 and 2019 With Report of Independent Registered Public Accounting Firm Hims, Inc. and Subsidiaries Consolidated Financial Statements Years Ended December 31, 2020 and 2019 Contents Report of Independent Registered Public Accounting Firm 1 Consolidated Financial Statements Consolidated Ba

Annual Report - 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact name of regi

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2021 (January 20, 2021) HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jur

- POS AM

Table of Contents As filed with the Securities and Exchange Commission on March 22, 2021.

Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results 2020 revenue grows 80% year-over-year to $148.8 million 2020 gross margin of 74%, compared to 54% in 2019 Closed merger with Oaktree Acquisition Corp. in Q1 2021

EX-99.1 Exhibit 99.1 Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results 2020 revenue grows 80% year-over-year to $148.8 million 2020 gross margin of 74%, compared to 54% in 2019 Closed merger with Oaktree Acquisition Corp. in Q1 2021 SAN FRANCISCO, March 18, 2021 – Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), a multi-specialty telehealth platform that con

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2021 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2021 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 005-91087 98-1482650 (State or other jurisdiction of incorporation) (Commission

Him & Hers Health, Inc. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants

Filed pursuant to Rule 424(b)(3) Registration No. 333-252814 PROSPECTUS SUPPLEMENT NO. 1 (to Prospectus dated February 12, 2021) Him & Hers Health, Inc. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants This prospectus supplement supplements the prospectus dated February 12, 2021 (t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 2) HIMS & HERS HEALTH, INC. (formerly Oaktree Acquisition Corp.) (Name of Issuer) CLASS A COMMON STOCK, PAR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 2) HIMS & HERS HEALTH, INC. (formerly Oaktree Acquisition Corp.) (Name of Issuer) CLASS A COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 433000106 (CUSIP Number) DECEMBER 31, 2020 (Date of event which requires filing of this stateme

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

CUSIP No. G67145105

240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) Oaktree Acquisition Corp. (Title of Class of Securities) Class A Ordinary Share, Par

HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants

424B3 1 d95702d424b3.htm 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-252814 PROSPECTUS HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants This prospectus relates to the offer and sale from time to time by the selling security

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) Hims & Hers Health, Inc. (Name of Issuer) CLASS A COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Secu

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) Hims & Hers Health, Inc. (Name of Issuer) CLASS A COMMON STOCK, PAR VALUE $0.0001 (Title of Class of Securities) 433000 106 (CUSIP Number) January 20, 2021 (Date of Event which Requires Filing of this Statement) Check the Appropriate Box to Desig

to Schedule 13G Joint Filing Agreement

EX-99.II Exhibit II to Schedule 13G Joint Filing Agreement The undersigned persons agree and consent to the joint filing on their behalf of this Schedule 13G dated February 12, 2021 in connection with their beneficial ownership of Oaktree Acquisition Corp. Each of Columbia Small Cap Growth Fund I and Columbia Management Investment Advisers, LLC authorizes Ameriprise Financial, Inc. to execute the

to Schedule 13G

EX-99.I Exhibit I to Schedule 13G Ameriprise Financial, Inc., a Delaware Corporation, is a parent holding company. The classification and identity of the relevant subsidiaries is as follows: Investment Adviser – Columbia Management Investment Advisers, LLC is an investment adviser registered under section 203 of the Investment Advisers Act of 1940.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities and Exchange Act of 1934 Oaktree Acquisition Corp (Name of Issuer) Class A Common Stock (Title of Class of Securities) (CUSIP Number) December 31, 2020 (Date

SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities and Exchange Act of 1934 Oaktree Acquisition Corp (Name of Issuer) Class A Common Stock (Title of Class of Securities) G67145105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is

-

Hims & Hers Health, Inc. 2269 Chestnut Street #523 San Francisco, California 94123 February 11, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street N.E. Washington, D.C. 20549 Attn: Abby Adams Re: Hims & Hers Health, Inc. Registration Statement on Form S-1 (File No. 333-252814) Ladies and Gentlemen: Hims & Hers Health, Inc. (the ?Company?) hereby request

- S-1/A

S-1/A Table of Contents As filed with the Securities and Exchange Commission on February 11, 2021.

Registration Statement - S-1

S-1 Table of Contents As filed with the Securities and Exchange Commission on February 5, 2021.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. __________

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. )* Hims & Hers Health, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value per share (Title of Class of Securities) 433000 106 (CUSIP Number) January

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Hims & Hers Health, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value (Title of Class of Secu

SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Hims & Hers Health, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value (Title of Class of Securities) 433000 106 (CUSIP Number) Andrew Dudum 2269 Chestnut Street, #523 San Francisco, California 94123 (415) 851-0195 (Name, Address and Tel

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. )* Hims & Hers Health, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securitie

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. )* Hims & Hers Health, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securitie

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. )* Hims & Hers Health, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securitie

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Hims & Hers Health, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Cla

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Hims & Hers Health, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 433000106 (CUSIP Number) January 20, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.     ) * Hims & Hers Health, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value per share (Title o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.     ) * Hims & Hers Health, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value per share (Title of Class of Securities) 433000 106 (CUSIP Number) January 20, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

EX-99.1 Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Defined terms included below have the same meaning as terms defined and included elsewhere in this Current Report on Form 8-K and, if not defined in the Form 8-K, the Proxy Statement/Prospectus. The following unaudited pro forma condensed combined balance sheet of New Hims as of September 30, 2020 and the unaudited p

Hims & Hers Health, Inc. 2020 Equity Incentive Plan and forms of agreement thereunder (incorporated by reference to Exhibit 10.6 to the Company’s Current Report on Form 8-K (File No. 001-38986), filed with the SEC on January 26, 2021)

Exhibit 10.6 HIMS & HERS HEALTH, INC. 2020 EQUITY INCENTIVE PLAN HIMS & HERS HEALTH, INC. 2020 EQUITY INCENTIVE PLAN ARTICLE 1. INTRODUCTION. The Board adopted the Plan to become effective immediately prior to the Closing (as defined in the Merger Agreement). The purpose of the Plan is to promote the long-term success of the Company and the creation of stockholder value by (a) encouraging Service

Registration Rights Agreement, dated as of January 20, 2021, by and among Hims & Hers Health, Inc. and Oaktree Acquisition Holdings, L.P. (incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K (File No. 001-38986), filed with the SEC on January 26, 2021).

EX-10.4 Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is entered into as of January 20, 2021, by and among Hims & Hers Health, Inc., a Delaware corporation, formerly known as Oaktree Acquisition Corp., a Cayman islands exempted company (the “Company”), and Oaktree Acquisition Holdings, L.P., a Cayman Islands exempted limited partnership (the “Spon

List of Subsidiaries (incorporated by reference to Exhibit 21.1 to the Company’s Current Report on Form 8-K (File No. 001-38986), filed with the SEC on January 26, 2021)

EX-21.1 Exhibit 21.1 SUBSIDIARIES OF HIMS & HERS HEALTH, INC. DOMESTIC COMPANIES Name Jurisdiction of Incorporation Hims, Inc. Delaware H&H Healthcare Management, Inc Delaware H&H Pharmacy Management, Inc. Delaware FOREIGN COMPANIES Name Jurisdiction of Incorporation Hims UK Limited United Kingdom

Hims, Inc. 2017 Stock Plan and forms of agreement thereunder (incorporated by reference to Exhibit 10.18 to the Company’s Current Report on Form 8-K (File No. 001-38986), filed with the SEC on January 26, 2021)

EX-10.18 Exhibit 10.18 HIMS, INC. 2017 STOCK PLAN ADOPTED ON JULY 13, 2017; AMENDED ON OCTOBER 21, 2020 TABLE OF CONTENTS Page SECTION 1. ESTABLISHMENT AND PURPOSE 1 SECTION 2. ADMINISTRATION 1 (a) Committees of the Board of Directors 1 (b) Authority of the Board of Directors 1 SECTION 3. ELIGIBILITY 1 (a) General Rule 1 (b) Ten-Percent Stockholders 1 SECTION 4. STOCK SUBJECT TO PLAN 2 (a) Basic L

Employment Agreement, dated as of January 14, 2021, by and between Hims, Inc. and Melissa Baird (incorporated by reference to Exhibit 10.16 to the Company’s Current Report on Form 8-K (File No. 001-38986), filed with the SEC on January 26, 2021)

EX-10.16 Exhibit 10.16 HIMS, INC. January 14, 2021 Melissa Baird Dear Melissa: Hims, Inc. (the “Company”) is pleased to offer you continuing employment on the following terms, effective as of the closing of the transactions contemplated by that certain Agreement and Plan of Merger by and among Oaktree Acquisition Corp., Rx Merger Sub, Inc. and the Company. 1. Position. Your title will be Chief Ope

Share Exchange Agreement, dated as of January 20, 2021, by and among Hims, Inc., Oaktree Acquisition Corp., Andrew Dudum and the Andrew Dudum 2015 Trust, Date July 2, 2015 (incorporated by reference to Exhibit 10.17 to the Company’s Current Report on Form 8-K (File No. 001-38986), filed with the SEC on January 26, 2021)

EX-10.17 Exhibit 10.17 SHARE EXCHANGE AGREEMENT by and among HIMS, INC., OAKTREE ACQUISITION CORP., ANDREW DUDUM and THE ANDREW DUDUM 2015 TRUST, DATED JULY 2, 2015 Dated as of January 20, 2021 THIS SHARE EXCHANGE AGREEMENT (this “Agreement”), dated as of January 20, 2021, is entered into by and among Hims, Inc., a Delaware corporation (“Hims”), Andrew Dudum (the “CEO”), The Andrew Dudum 2015 Trus

Certificate of Incorporation of Hims & Hers Health, Inc. (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-38986), filed with the SEC on January 26, 2021).

EX-3.1 Exhibit 3.1 CERTIFICATE OF INCORPORATION OF HIMS & HERS HEALTH, INC. ARTICLE I The name of the corporation is Hims & Hers Health, Inc. (hereinafter called the “Corporation”). ARTICLE II The address of the registered office of the Corporation in the State of Delaware is 1209 Orange Street, City of Wilmington, County of New Castle, Zip Code 19801. The name of the registered agent of the Corpo

Certificate of Corporate Domestication of Oaktree Acquisition Corp. (incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K (File No. 001-38986), filed with the SEC on January 26, 2021).

EX-4.3 Exhibit 4.3 CERTIFICATE OF CORPORATE DOMESTICATION OF OAKTREE ACQUISITION CORP. Pursuant to Section 388 of the General Corporation Law of the State of Delaware Oaktree Acquisition Corp., presently a Cayman Islands exempted company limited by shares (the “Company”), DOES HEREBY CERTIFY: 1. The Company was first incorporated on April 9, 2019 under the laws of the Cayman Islands. 2. The name o

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Change in Shell Company Status, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant, Completion of Acquisition or Disposition of Assets - FORM 8-K

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 20, 2021 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation)

Change in Control and Severance Agreement, dated as of December 21, 2020, by and between Hims, Inc. and Melissa Baird (incorporated by reference to Exhibit 10.13 to the Company’s Current Report on Form 8-K (File No. 001-38986), filed with the SEC on January 26, 2021).

EX-10.13 Exhibit 10.13 HIMS, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control Severance Agreement (the “Agreement”) is made and entered into by and between Melissa Baird (the “Executive”) and Hims, Inc., a Delaware corporation (the “Company”), effective as of the date specified in Section 1 below. This Agreement provides severance and acceleration benefits in connection with c

Letter from WithumSmith+Brown, PC to the SEC, dated January 26, 2021.

Exhibit 16.1 January 26, 2021 Office of the Chief Accountant Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Ladies and Gentlemen: We have read the statements of Hims & Hers Health, Inc. (formally known as Oaktree Acquisition Corp.) included under Item 4.01 of its Form 8-K dated January 26, 2021. We agree with the statements concerning our Firm under Item 4.01, in which

Bylaws of Hims & Hers Health, Inc. (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K (File No. 001-38986), filed with the SEC on January 26, 2021).

EX-3.2 3 d108056dex32.htm EX-3.2 Table of Contents Exhibit 3.2 Hims & Hers Health, Inc. Bylaws Table of Contents Table of Contents Page Article I Stockholders 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 1 1.5 Voting List 1 1.6 Quorum 2 1.7 Adjournments 2 1.8 Voting and Proxies 2 1.9 Action at Meeting 2 1.10 Stockholder Action by Written Consent 3 1.

Form of Hims & Hers Health, Inc. 2020 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.7 to the Company’s Current Report on Form 8-K (File No. 001-38986), filed with the SEC on January 26, 2021).

EX-10.7 Exhibit 10.7 HIMS & HERS HEALTH, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN HIMS & HERS HEALTH, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN SECTION 1. PURPOSE OF THE PLAN. The Board adopted the Plan to become effective immediately prior to the Closing (as defined in the Merger Agreement). The purpose of the Plan is to provide Eligible Employees with an opportunity to increase their proprietary inte

EX-99.25

NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on February 01, 2021, pursuant to the provisions of Rule 12d2-2 (a).

Submission of Matters to a Vote of Security Holders - 8-K

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 19, 2021 OAKTREE ACQUISITION CORP.

Merger Prospectus - 425

425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 19, 2021 OAKTREE ACQUISITION CORP.

Other Events - FORM 8-K

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 15, 2021 OAKTREE ACQUISITION CORP.

Merger Prospectus - FORM 8-K

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 15, 2021 OAKTREE ACQUISITION CORP.

Financial Statements and Exhibits, Other Events - FORM 8-K

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 12, 2021 OAKTREE ACQUISITION CORP.

Item Preview: English (US)

EX-99.1 Exhibit 99.1 Item Preview: English (US) Oaktree Acquisition Corp. Announces Extraordinary General Meeting Teleconference Details NEW YORK—(BUSINESS WIRE)—Oaktree Acquisition Corp. (“OAC”) (NYSE: OAC), today announced that, due to the public health and safety concerns related to the coronavirus (COVID-19) pandemic and recommendations and orders from federal and New York authorities, OAC is

Item Preview: English (US)

EX-99.1 Exhibit 99.1 Item Preview: English (US) Oaktree Acquisition Corp. Announces Extraordinary General Meeting Teleconference Details NEW YORK—(BUSINESS WIRE)—Oaktree Acquisition Corp. (“OAC”) (NYSE: OAC), today announced that, due to the public health and safety concerns related to the coronavirus (COVID-19) pandemic and recommendations and orders from federal and New York authorities, OAC is

Merger Prospectus - FORM 8-K

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 12, 2021 OAKTREE ACQUISITION CORP.

Merger Prospectus - 425

425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 6, 2021 OAKTREE ACQUISITION CORP.

Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 6, 2021 OAKTREE ACQUISITION CORP.

Oaktree Acquisition Corp. Reminds Shareholders to Vote in Favor of the Business Combination with Hims & Hers

EX-99.1 Exhibit 99.1 Oaktree Acquisition Corp. Reminds Shareholders to Vote in Favor of the Business Combination with Hims & Hers Los Angeles — January 6, 2021 — Oaktree Acquisition Corp. (NYSE: OAC.U, OAC, OAC WS) (“the Company”), a special purpose acquisition company sponsored by an affiliate of Oaktree Capital Management, L.P. (“Oaktree”), reminds its shareholders to vote in favor of the approv

CUSIP No. G67145105

240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.)* (Name of Issuer) Oaktree Acquisition Corp. (Title of Class of Securities) Class A Ordinary Share, Par Va

JOINT FILING AGREEMENT

Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi

PROXY STATEMENT FOR EXTRAORDINARY GENERAL MEETING OF OAKTREE ACQUISITION CORP. PROSPECTUS FOR 33,619,270 SHARES OF CLASS A COMMON STOCK AND 9,720,833 WARRANTS OF OAKTREE ACQUISITION CORP. (AFTER ITS DOMESTICATION AS A CORPORATION INCORPORATED IN THE

424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-249622 PROXY STATEMENT FOR EXTRAORDINARY GENERAL MEETING OF OAKTREE ACQUISITION CORP. PROSPECTUS FOR 33,619,270 SHARES OF CLASS A COMMON STOCK AND 9,720,833 WARRANTS OF OAKTREE ACQUISITION CORP. (AFTER ITS DOMESTICATION AS A CORPORATION INCORPORATED IN THE STATE OF DELAWARE, WHICH WILL BE RENAMED HIMS & HERS HEALTH, INC.

Oaktree Acquisition Corp. 333 South Grand Avenue, 28th Floor Los Angeles, California 90071 December 28, 2020

Oaktree Acquisition Corp. 333 South Grand Avenue, 28th Floor Los Angeles, California 90071 December 28, 2020 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Laura Crotty Re: Oaktree Acquisition Corp. Registration Statement on Form S-4 (the ?Registration Statement?) File No. 333-249622 Ladies a

Change in Control and Severance Agreement, dated as of December 21, 2020, by and between Hims and Andrew Dudum (incorporated by reference to Exhibit 10.16 to the Registrant’s Proxy Statement/Prospectus on Form S-4/A filed with the SEC on December 22, 2020).

EX-10.16 Exhibit 10.16 HIMS, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control Severance Agreement (the “Agreement”) is made and entered into by and between Andrew Dudum (the “Executive”) and Hims, Inc., a Delaware corporation (the “Company”), effective as of the date specified in Section 1 below. This Agreement provides severance and acceleration benefits in connection with ce

Employment Agreement, dated as of December 21, 2020, by and between Hims, Inc. and Spencer Lee (incorporated by reference to Exhibit 10.17 to Oaktree Acquisition Corp.’s Registration Statement on Form S-4/A (Registration No. 333-249622), filed with the SEC on December 22, 2020)

EX-10.17 Exhibit 10.17 HIMS, INC. December 21, 2020 Spencer Lee Dear Spencer: Hims, Inc. (the “Company”) is pleased to offer you continuing employment on the following terms, effective as of the closing of the transactions contemplated by that certain Agreement and Plan of Merger by and among Oaktree Acquisition Corp., Rx Merger Sub, Inc. and the Company. 1. Position. Your title will be Chief Fina

Form of Share Exchange Agreement by and among Hims, Oaktree Acquisition Corp., Andrew Dudum and the Andrew Dudum 2015 Trust, Date July 2, 2015 (incorporated by reference to Exhibit 10.19 to the Registrant’s Proxy Statement/Prospectus on Form S-4/A filed with the SEC on December 22, 2020).

EX-10.19 Exhibit 10.19 SHARE EXCHANGE AGREEMENT by and among HIMS, INC., OAKTREE ACQUISITION CORP., ANDREW DUDUM and THE ANDREW DUDUM 2015 TRUST, DATED JULY 2, 2015 Dated as of [•], 2020 THIS SHARE EXCHANGE AGREEMENT (this “Agreement”), dated as of [•], 2020, is entered into by and among Hims, Inc., a Delaware corporation (“Hims”), Andrew Dudum (the “CEO”), The Andrew Dudum 2015 Trust, dated July

Change in Control and Severance Agreement, dated as of December 21, 2020, by and between Hims, Inc. and Spencer Lee (incorporated by reference to Exhibit 10.15 to Oaktree Acquisition Corp.’s Registration Statement on Form S-4/A (Registration No. 333-249622), filed with the SEC on December 22, 2020)

EX-10.15 Exhibit 10.15 HIMS, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control Severance Agreement (the “Agreement”) is made and entered into by and between Spencer Lee (the “Executive”) and Hims, Inc., a Delaware corporation (the “Company”), effective as of the date specified in Section 1 below. This Agreement provides severance and acceleration benefits in connection with cer

- S-4/A

S-4/A Table of Contents As filed with the Securities and Exchange Commission on December 22, 2020 No.

Employment Agreement, dated as of December 21, 2020, by and between Hims and Andrew Dudum (incorporated by reference to Exhibit 10.19 to the Registrant’s Proxy Statement/Prospectus on Form S-4/A filed with the SEC on December 22, 2020).

EX-10.18 Exhibit 10.18 HIMS, INC. December 21, 2020 Andrew Dudum Dear Andrew: Hims, Inc. (the “Company”) is pleased to offer you continuing employment on the following terms, effective as of the closing of the transactions contemplated by that certain Agreement and Plan of Merger by and among Oaktree Acquisition Corp., Rx Merger Sub, Inc. and the Company. 1. Position. Your title will be Chief Exec

Form of Indemnification Agreement (incorporated by reference to Exhibit 10.8 to the Registrant’s Proxy Statement/Prospectus on Form S-4/A filed with the SEC on December 22, 2020).

EX-10.8 2 d47481dex108.htm EX-10.8 Exhibit 10.8 Indemnification Agreement This Indemnification Agreement (“Agreement”) is made as of , 2020 by and between Hims & Hers Health, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering the subject matter of this Agreement. Recita

Oaktree Acquisition Corp. 333 South Grand Avenue, 28th Floor Los Angeles, CA 90071 December 22, 2020

Oaktree Acquisition Corp. 333 South Grand Avenue, 28th Floor Los Angeles, CA 90071 December 22, 2020 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Trade & Services 100 F Street, NE Washington, D.C. 20549 Attention: Tracey McKoy Re: Oaktree Acquisition Corp. Amendment No. 1 to Registration Statement on Form S-4 Filed October 23, 2020 File No. 333-249622 Dear

Form of Certificate of Corporate Domestication of OAC, to be filed with the Secretary of the State of Delaware.

EX-4.5 Exhibit 4.5 CERTIFICATE OF CORPORATE DOMESTICATION OF OAKTREE ACQUISITION CORP. Pursuant to Section 388 of the General Corporation Law of the State of Delaware Oaktree Acquisition Corp., presently a Cayman Islands exempted company limited by shares (the “Company”), DOES HEREBY CERTIFY: 1. The Company was first incorporated on April 9, 2019 under the laws of the Cayman Islands. 2. The name o

Employment Agreement, dated as of March 21, 2019, by and between Hims and Charles Henrich.

EX-10.11 Exhibit 10.11 Hims, Inc. One Letterman Drive Suite C3500 San Francisco, CA 94129 March 21, 2019 Charles Henrich Re: Offer Letter and Employment Terms Dear Charles: 1. Position. HIMS, INC., (the “Company”) is pleased to offer you the position of Chief Technology Officer, Hims & Hers, reporting to the Chief Executive Officer of the Company, on the following terms. You will work at our facil

Oaktree Acquisition Corp. 333 South Grand Avenue, 28th Floor Los Angeles, CA 90071 December 2, 2020

Oaktree Acquisition Corp. 333 South Grand Avenue, 28th Floor Los Angeles, CA 90071 December 2, 2020 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Trade & Services 100 F Street, NE Washington, D.C. 20549 Attention: Tracey McKoy Re: Oaktree Acquisition Corp. Registration Statement on Form S-4 Filed October 23, 2020 File No. 333-249622 Dear Ms. McKoy: This let